Federal Requirements Study Guide

Federal Requirements accounts for 12.5% of the PTCE (approximately 11 out of 90 scored questions). This domain covers federal laws and regulations that govern pharmacy practice, including DEA regulations for controlled substances, HIPAA privacy and security rules, FDA drug approval and labeling, OBRA 90, the Combat Methamphetamine Epidemic Act (CMEA), the Poison Prevention Packaging Act, the Drug Supply Chain Security Act (DSCSA), prescription requirements, and record-keeping obligations. While this is the smallest domain by weight, the questions are very specific and require memorization of key regulatory details.

The Drug Enforcement Administration (DEA) enforces the Controlled Substances Act (CSA). Key DEA regulations for the PTCE: Every prescriber must have a valid DEA number to prescribe controlled substances. The DEA number format: two letters followed by seven digits. The first letter indicates the prescriber type (A, B, or F for practitioners; M for mid-level practitioners). To verify a DEA number: add the 1st, 3rd, and 5th digits, then add twice the sum of the 2nd, 4th, and 6th digits. The last digit of the total should match the 7th digit (the check digit). Schedule II prescriptions require a written or electronic prescription (no phone-in except in emergencies). Partial fills of CII prescriptions must be dispensed within 72 hours (or 60 days for LTCF/terminally ill patients). DEA Form 222 is required to order Schedule II substances. DEA Form 41 is used for destruction of controlled substances. Perpetual inventory is required for Schedule II drugs.

The Health Insurance Portability and Accountability Act (HIPAA) protects patient health information (PHI). Key HIPAA concepts for the PTCE: PHI includes any individually identifiable health information (name, address, DOB, prescription records, diagnoses). The Privacy Rule governs the use and disclosure of PHI. The Security Rule applies specifically to electronic PHI (ePHI). The Minimum Necessary Standard requires that only the minimum PHI needed be accessed or disclosed. Treatment, Payment, and Healthcare Operations (TPO) are permitted uses of PHI without patient authorization. Patients have the right to access their records, request amendments, and receive an accounting of disclosures. Notice of Privacy Practices (NPP) must be provided to patients. Business Associate Agreements (BAAs) are required for third parties who handle PHI. Violations can result in civil and criminal penalties.

The Food and Drug Administration (FDA) oversees drug safety and approval. Key FDA concepts: The drug approval process includes preclinical testing, Investigational New Drug (IND) application, three phases of clinical trials, New Drug Application (NDA), and post-market surveillance (Phase IV). Generic drugs must demonstrate bioequivalence to the brand-name drug via an Abbreviated New Drug Application (ANDA). The FDA Recall classifications: Class I (reasonable probability of serious adverse health consequences or death), Class II (may cause temporary or medically reversible adverse health consequences), Class III (not likely to cause adverse health consequences). The FDA Orange Book lists approved drug products with therapeutic equivalence evaluations. MedWatch is the FDA safety reporting program for healthcare professionals and consumers. National Drug Code (NDC) numbers have three segments: labeler code, product code, and package code.

The Omnibus Budget Reconciliation Act of 1990 (OBRA 90) requires pharmacists to perform Drug Utilization Review (DUR) and offer patient counseling for Medicaid patients (many states extended this to all patients). DUR includes prospective review (before dispensing), concurrent review (during therapy), and retrospective review (after dispensing). The Combat Methamphetamine Epidemic Act (CMEA) of 2005 restricts the sale of pseudoephedrine and ephedrine products. Pseudoephedrine must be stored behind the counter or in a locked cabinet. Buyers must show valid ID and sign a logbook. Daily limit: 3.6 grams. Monthly limit: 9 grams (7.5 grams if mail order). The Poison Prevention Packaging Act (PPPA) requires child-resistant containers for most prescription medications. Exceptions include sublingual nitroglycerin, oral contraceptives in manufacturer packaging, and prescriptions where the patient or prescriber requests non-child-resistant packaging.

Federal Requirements questions are highly factual. Make flashcards for key numbers (refill limits, purchase limits, DEA form numbers, recall classifications). Practice DEA number verification calculations. Know which controlled substance schedules allow refills and how many. Memorize the HIPAA TPO exceptions. PTCBprep by Arteura includes targeted flashcards and mini exams covering all the specific regulatory facts tested on the PTCE.